Irinotecan
Cervical Adenosquamous Carcinoma
Mayo ClinicSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Cervical Adenosquamous Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II Uganda Cancer Institute | Phase 2 | BB |
PEGFILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Hycamtin National Cancer Institute (NCI) | Phase 2 | B |
Vinorelbine National Cancer Institute (NCI) | Phase 2 | B |
Cediranib Mayo Clinic | Phase 1 | CC |
(+)-VINCRISTINE Mayo Clinic | Phase 1 | CC |
ava6103 Avacta Life Sciences Ltd | Phase 1 | CC |
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →